Depo-subQ provera 104 FDA Approval History
FDA Approved: Yes (First approved December 17, 2004)
Brand name: depo-subQ provera 104
Generic name: medroxyprogesterone acetate
Dosage form: Injection
Company: Pfizer Inc.
Treatment for: Birth Control
depo-subQ provera 104 (medroxyprogesterone acetate) is a lower dose, subcutaneous formulation of Depo Provera indicated for the prevention of pregnancy in women of child bearing potential.
Development timeline for depo-subQ provera 104
|Dec 17, 2004||Approval depo-subQ provera 104 Pfizer Inc. - Treatment for Prevention of Pregnancy|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.